|
Sign In to gain access to subscriptions and/or personal tools.
|
Click on image to view larger version.
Figure. All CUS sera studied have antibodies to  Np63 , and 52% have serum IgA. Western transfers of deltaNp63alpha protein, produced by in vitro transcription/translation, were immunoblotted with sera. (A,B) Results from 21 different CUS patient sera (numbered lanes) and the mAb 4A4. [Lane #/serum #, as follows: 1/572, 2/3069, 3/4045, 4/4787, 5/4792, 6/9264, 7/8985, 8/9035, 9/8051, 10/5742, 11/622, 12/8216, 13/S.J., 14/180, 15/1631, 16/10808, 17/512; 18E47; 19/E67; 20/E81; 21/IM0017.] (A) All of the sera have antibodies to deltaNp63alpha protein. (B) Eleven of the 21 sera have IgA antibodies detected with goat anti-human IgA secondary antibody. (C) Control sera tested were 16 diagnostic samples from patients with clinical dermatologic or rheumatic conditions. None of the controls had antibodies to deltaNp63alpha protein. mAb = monoclonal antibody, MW = molecular-weight marker.
J DENT RES, Vol. 86, No. 9,
826-831 (2007)
DOI: 10.1177/154405910708600904
|
|
